应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00867 康哲药业
未开盘 08-15 16:08:14
6.650
+0.030
+0.45%
最高
6.740
最低
6.560
成交量
209.10万
今开
6.580
昨收
6.620
日振幅
2.72%
总市值
162.23亿
流通市值
162.23亿
总股本
24.40亿
成交额
1,393万
换手率
0.09%
流通股本
24.40亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
【港股通】康哲药业(00867)中期净利润同比减少52.6%
金吾财讯 · 08-15 23:11
【港股通】康哲药业(00867)中期净利润同比减少52.6%
康哲药业(00867):陈洪兵辞任首席营运官及副总裁 并调任为非执行董事
智通财经 · 08-15 22:24
康哲药业(00867):陈洪兵辞任首席营运官及副总裁 并调任为非执行董事
康哲药业(00867)上半年溢利约9.03亿元 环比增长92.8%
智通财经网 · 08-15 22:20
康哲药业(00867)上半年溢利约9.03亿元 环比增长92.8%
康哲药业(00867)将于9月9日派发中期股息每股0.1507元
智通财经 · 08-15 22:17
康哲药业(00867)将于9月9日派发中期股息每股0.1507元
【券商聚焦】华福证券首予康哲药业(00867)“买入”评级 指其创新管线步入兑现期
金吾财讯 · 08-15 11:22
【券商聚焦】华福证券首予康哲药业(00867)“买入”评级 指其创新管线步入兑现期
下周备忘
阿斯达克财经 · 08-09
下周备忘
康哲药业08月07日主力资金流入134万元 连续3日加仓
自选股智能写手 · 08-07
康哲药业08月07日主力资金流入134万元 连续3日加仓
康哲药业08月06日获主力加仓329万元 环比增加422.22%
自选股智能写手 · 08-06
康哲药业08月06日获主力加仓329万元 环比增加422.22%
康哲药业现涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
新浪港股 · 08-06
康哲药业现涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
【港股异动 | 康哲药业(00867.HK)涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批】智通财经APP获悉,康哲药业(00867.
智通财经 · 08-06
【港股异动 | 康哲药业(00867.HK)涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批】智通财经APP获悉,康哲药业(00867.
港股异动 | 康哲药业(00867)涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
智通财经 · 08-06
港股异动 | 康哲药业(00867)涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
康哲药业:甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
新浪港股 · 08-06
康哲药业:甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
智通港股早知道 | 隔夜美股三大股指集体大跌 五部门:加强金融支持乡村全面振兴专项行动
智通财经 · 08-06
智通港股早知道 | 隔夜美股三大股指集体大跌 五部门:加强金融支持乡村全面振兴专项行动
康哲药业(00867.HK)氨蝶呤注射液增加适应症上市许可申请获批
阿斯达克财经 · 08-06
康哲药业(00867.HK)氨蝶呤注射液增加适应症上市许可申请获批
迪卡斯:康哲药业获得Hepzato套件的CMS Ntap状态。
智通财经 · 08-05
迪卡斯:康哲药业获得Hepzato套件的CMS Ntap状态。
【康龙化成(03759.HK)和合作方共同对新加坡合资公司追加投资2000万美元】智通财经APP讯,康龙化成(03759.
智通财经 · 08-05
【康龙化成(03759.HK)和合作方共同对新加坡合资公司追加投资2000万美元】智通财经APP讯,康龙化成(03759.
康哲药业(00867):甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
智通财经 · 08-05
康哲药业(00867):甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批
【康哲药业(00867.HK):甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批】智通财经APP讯,康哲药业(00867.
智通财经 · 08-05
【康哲药业(00867.HK):甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批】智通财经APP讯,康哲药业(00867.
康哲药业(00867.HK)将于8月15日召开董事会会议以审批中期业绩
格隆汇资讯 · 08-05
康哲药业(00867.HK)将于8月15日召开董事会会议以审批中期业绩
南向资金8月2日净买入康哲药业10.10万股 连续7日增持
自选股智能写手 · 08-05
南向资金8月2日净买入康哲药业10.10万股 连续7日增持
加载更多
公司概况
公司名称:
康哲药业
所属市场:
SEHK
上市日期:
--
主营业务:
康哲药业控股有限公司是一家主要从事医药产品的制造、推广、营销及销售业务的香港投资控股公司。其直接网络主要产品包括黛力新、优思弗、新活素、莎尔福、亿活及施图伦滴眼液等。其代理商推广网络产品包括沙多力卡、伊诺舒及喜达康等。其产品用于治疗胃病、心脏病、外伤感染、肝病及眼疾等。
发行价格:
--
{"stockData":{"symbol":"00867","market":"HK","secType":"STK","nameCN":"康哲药业","latestPrice":6.65,"timestamp":1723709294009,"preClose":6.62,"halted":0,"volume":2091000,"delay":0,"floatShares":2439528512,"shares":2439528512,"eps":1.0628552,"marketStatus":"未开盘","marketStatusCode":0,"change":0.03,"latestTime":"08-15 16:08:14","open":6.58,"high":6.74,"low":6.56,"amount":13929545,"amplitude":0.02719,"askPrice":6.66,"askSize":16000,"bidPrice":6.65,"bidSize":41000,"shortable":3,"etf":0,"ttmEps":1.062855201396955,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1723771800000},"adr":0,"adjPreClose":6.62,"dividendRate":0.064241,"openAndCloseTimeList":[[1723685400000,1723694400000],[1723698000000,1723708800000]],"volumeRatio":1.103962544554785,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00867","defaultTab":"news","newsList":[{"id":"2459471315","title":"【港股通】康哲药业(00867)中期净利润同比减少52.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459471315","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459471315?lang=zh_cn&edition=full","pubTime":"2024-08-15 23:11","pubTimestamp":1723734701,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康哲药业(00867)公布截至2024年6月30日的中期业绩。公司拥有人应占期间溢利9.1亿元(人民币,下同),同比减少52.6%。每股基本盈利0.3734元。拟派中期股息每股0.1507元期内公司营业额36.11亿元,同比减少21.67%。公告称,集团优思弗、波依定继续执行第八批国家带量采购(国采),对经营业绩产生负面影响;三个国采产品(黛力新、优思弗、波依定)全按药品销售收入口径同比去年同期减少人民币11.97亿元,同比下降49.2%。2024年上半年,集团非国采独家产品及创新产品全按药品销售收入合计为人民币24.05亿元,占全按药品销售收入计算营业额的56.1%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OGM2MzIwM2IyYjUyODE2Mjg1OTAxODk2OTQ=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OGM2MzIwM2IyYjUyODE2Mjg1OTAxODk2OTQ=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942398","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","00867","HSTECH","YANG"],"gpt_icon":1},{"id":"2459947559","title":"康哲药业(00867):陈洪兵辞任首席营运官及副总裁 并调任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2459947559","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459947559?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:24","pubTimestamp":1723731872,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康哲药业(00867)公布,陈洪兵辞任首席营运官及副总裁,并由执行董事调任为非执行董事,自2024年8月15日生效,以投入更多时间于个人事务。同时,陈洪兵已获公司聘任为资深顾问。陈洪兵的工作事务将由担任公司副总经理兼渠道与院外市场总经理的樊杰、担任公司副总经理兼战略市场总经理的蔡平,以及公司现有的高管团队承接。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","SG9999015952.SGD","00867","BK1593","LU2488822045.USD","SG9999015945.SGD","SG9999015978.USD","SG9999004220.SGD","BK1191"],"gpt_icon":0},{"id":"2459475555","title":"康哲药业(00867)上半年溢利约9.03亿元 环比增长92.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459475555","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459475555?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:20","pubTimestamp":1723731641,"startTime":"0","endTime":"0","summary":"康哲药业(00867)公布2024年中期业绩,营业额约人民币36.11亿元,环比增...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_43.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_43.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["SG9999015945.SGD","SG9999015952.SGD","00867","BK1191","SG9999015986.USD","BK1593","SG9999004220.SGD","SG9999015978.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2459473089","title":"康哲药业(00867)将于9月9日派发中期股息每股0.1507元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459473089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459473089?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:17","pubTimestamp":1723731427,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康哲药业(00867)发布公告,将于2024年9月9日派发截至2024年6月30日止六个月的中期股息每股0.1507元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1165048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015952.SGD","00867","SG9999004220.SGD","SG9999015945.SGD","BK1191","SG9999015978.USD","BK1593","LU2488822045.USD","SG9999015986.USD"],"gpt_icon":0},{"id":"2459462681","title":"【券商聚焦】华福证券首予康哲药业(00867)“买入”评级 指其创新管线步入兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2459462681","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459462681?lang=zh_cn&edition=full","pubTime":"2024-08-15 11:22","pubTimestamp":1723692120,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华福证券发研指,康哲药业 发展分为3阶段,早期业务以进口原研药代理销售为主,期间先后获得了黛力新、优思弗等核心单品在中国大陆的独家推广及销售权。创新管线的成功兑现有望打开公司第二增长曲线。该行认为公司为创新转型的平台型药企,商业化能力经过长期验证,创新管线步入兑现期,在售产品集采利空落地,首次覆盖给予“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/MmVhZTZkMDM4NGVmNGFjNGI4NWVlMGI4Yzg3MDVjMjMzODE0Mjk0ODA4MTA0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MmVhZTZkMDM4NGVmNGFjNGI4NWVlMGI4Yzg3MDVjMjMzODE0Mjk0ODA4MTA0.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1942345","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867","161027"],"gpt_icon":0},{"id":"2458557736","title":"下周备忘","url":"https://stock-news.laohu8.com/highlight/detail?id=2458557736","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458557736?lang=zh_cn&edition=full","pubTime":"2024-08-09 18:09","pubTimestamp":1723198140,"startTime":"0","endTime":"0","summary":"8月12日(周一)日本、泰国股市假期休市*中国首七月外商直接投资:前值跌29.1%*中国7月M2货币供应年率:预测升6%;前值升6.2%*中国首七月新增人民币贷款:预测13.7万亿;首六个月13.2621万亿*中国首七月社会融资规模增量:预测19.0995万亿人民币;首六个月18.0992万亿人民币*印度7月CPI年率:预测3.65%;前值5.08%*印度6月工业生产年率:预测5.3%;前值5.9","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180508151843732_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180508151843732_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1370483/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01928","01270","01083","01503","01313","03813","00435","01128","00027","00066","02099","09863","09995","00772","00354","00288","01071","02588","00808","00127","01177","02331","02858","01883","00709","01038","01415","01234","00763","01857","01208","01316","00867","03709","01698","02423","06618","02191","09985","00405","06088","00775","00806","01910","00268","00906","00062","00762","00992","00551"],"gpt_icon":0},{"id":"2457896322","title":"康哲药业08月07日主力资金流入134万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2457896322","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457896322?lang=zh_cn&edition=full","pubTime":"2024-08-07 16:15","pubTimestamp":1723018516,"startTime":"0","endTime":"0","summary":"08月07日, 康哲药业股价涨1.34%,报收6.79元,成交金额2562万元,换手率0.15%,振幅3.88%,量比0.88。康哲药业今日主力资金净流入134万元,连续3日净流入,上一交易日主力净流入329万元,今日环比减少59.27%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为63.64%,平均涨幅为1.49%。该股近5个交易日上涨6.17%,主力资金累计净流入618万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入1292万元,其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080716152595853d4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080716152595853d4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015945.SGD","SG9999015952.SGD","00867","BK1191","SG9999015986.USD","BK1593","SG9999004220.SGD","SG9999015978.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2457844094","title":"康哲药业08月06日获主力加仓329万元 环比增加422.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457844094","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457844094?lang=zh_cn&edition=full","pubTime":"2024-08-06 16:15","pubTimestamp":1722932115,"startTime":"0","endTime":"0","summary":"08月06日, 康哲药业股价涨4.52%,报收6.70元,成交金额2767万元,换手率0.17%,振幅4.52%,量比0.87。康哲药业今日主力资金净流入329万元,上一交易日主力净流入63万元,今日环比增加422.22%。该股近5个交易日上涨7.21%,主力资金累计净流入607万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入978万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061615279581d78e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408061615279581d78e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999004220.SGD","BK1593","SG9999015978.USD","SG9999015945.SGD","LU2488822045.USD","SG9999015952.SGD","SG9999015986.USD","00867","BK1191"],"gpt_icon":0},{"id":"2457054592","title":"康哲药业现涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2457054592","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457054592?lang=zh_cn&edition=full","pubTime":"2024-08-06 11:26","pubTimestamp":1722914795,"startTime":"0","endTime":"0","summary":"康哲药业(00867)早盘股价上涨3.43%,现报6.63港元,成交额707.54万港元。\n 康哲药业发布公告,甲氨蝶呤注射液(产品)增加适应症的上市许可申请(NDA)已于2024年7月30日获得国家药品监督管理局(NMPA)批准。产品是多种规格的预充式小容量甲氨蝶呤注射剂,获批用于治疗成人活动性类风湿关节炎(RA)。集团于2024年8月5日获得药品注册证书。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-06/doc-inchsmtm6997992.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-06/doc-inchsmtm6997992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["SG9999015945.SGD","BK1191","LU2488822045.USD","SG9999015978.USD","BK1593","SG9999015952.SGD","SG9999015986.USD","00867","SG9999004220.SGD"],"gpt_icon":0},{"id":"2457305911","title":"【港股异动 | 康哲药业(00867.HK)涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批】智通财经APP获悉,康哲药业(00867.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457305911","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457305911?lang=zh_cn&edition=full","pubTime":"2024-08-06 11:04","pubTimestamp":1722913452,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015945.SGD","SG9999015952.SGD","BK1593","BK1191","LU2488822045.USD","SG9999015978.USD","SG9999015986.USD","00867","SG9999004220.SGD"],"gpt_icon":0},{"id":"2457059115","title":"港股异动 | 康哲药业(00867)涨超3% 甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2457059115","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457059115?lang=zh_cn&edition=full","pubTime":"2024-08-06 11:04","pubTimestamp":1722913452,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康哲药业(00867)涨超3%,截至发稿,涨3.43%,报6.63港元,成交额637.95万港元。消息面上,康哲药业发布公告,甲氨蝶呤注射液(产品)增加适应症的上市许可申请(NDA)已于2024年7月30日获得国家药品监督管理局(NMPA)批准。产品是多种规格的预充式小容量甲氨蝶呤注射剂,获批用于治疗成人活动性类风湿关节炎(RA)。集团于2024年8月5日获得药品注册证书。据悉,甲氨蝶呤是国际公认治疗类风湿关节炎(RA)的一线首选药物和锚定药物。产品已获得瑞士、英国等21个欧洲国家主管部门批准,目前已在包括欧盟、澳大利亚和中国等在内的全球47个国家和地区上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015952.SGD","SG9999015945.SGD","SG9999015978.USD","LU2488822045.USD","BK1191","00867","SG9999004220.SGD","BK1593","SG9999015986.USD"],"gpt_icon":0},{"id":"2457038007","title":"康哲药业:甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2457038007","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457038007?lang=zh_cn&edition=full","pubTime":"2024-08-06 07:54","pubTimestamp":1722902057,"startTime":"0","endTime":"0","summary":"康哲药业(00867)发布公告,甲氨蝶呤注射液(产品)增加适应症的上市许可申请(NDA)已于2024年7月30日获得国家药品监督管理局(NMPA)批准。产品是多种规格的预充式小容量甲氨蝶呤注射剂,获批用于治疗成人活动性类风湿关节炎(RA)。集团于2024年8月5日获得药品注册证书。\n 甲氨蝶呤是国际公认治疗类风湿关节炎(RA)的一线首选药物和锚定药物。产品是中国首个以皮下给药方式治疗类风湿关节炎(RA)的预充式甲氨蝶呤注射液,为成人活动性类风湿关节炎(RA)患者提供更加安全、有效、便捷、精准的给药方案。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-06/doc-inchsfmp7051507.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-08-06/doc-inchsfmp7051507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1191","SG9999015952.SGD","LU2488822045.USD","SG9999015986.USD","00867","BK1593","SG9999004220.SGD","SG9999015945.SGD","SG9999015978.USD"],"gpt_icon":0},{"id":"2457038465","title":"智通港股早知道 | 隔夜美股三大股指集体大跌 五部门:加强金融支持乡村全面振兴专项行动","url":"https://stock-news.laohu8.com/highlight/detail?id=2457038465","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457038465?lang=zh_cn&edition=full","pubTime":"2024-08-06 07:40","pubTimestamp":1722901201,"startTime":"0","endTime":"0","summary":"集团于2024年8月5日获得药品注册证书。总收入,经营利润,每股盈利均创历年Q2新高。肯德基本季度净新增门店 328 家,其中加盟店净新增 74 家,占比 23%。必胜客本季度系统销售额在去年高基数的情况下同比增长 1%,主要得益于本季度 8%的净新增门店贡献。截至 2024 年 6 月 30 日,门店总数达 3,504 家。经营利润同比增长 13% 至 4,000 万美元,创第二季度新高。本季度外卖销售增长 6%,约占必胜客餐厅收入的 38%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159940","BK1170","BK1604","LU1969619763.USD","SG9999015978.USD","SG9999015952.SGD","BK1583","BK1191","BK1228","BK1508","YANG","HSTECH","LU2328871848.SGD","SG9999001051.SGD","BK1593","SG9999015986.USD","BK1596","06088","LU0640798160.USD","SG9999001093.SGD","LU1115378108.SGD","HSCEI","01769","BK1556","BK1516","SGXZ90724238.SGD","00780","00867","BK1164","BK1574","SG9999015945.SGD","SG9999004220.SGD","BK1161","SG9999001226.SGD","LU2460026573.USD","LU2488822045.USD","BK1519"],"gpt_icon":1},{"id":"2457870361","title":"康哲药业(00867.HK)氨蝶呤注射液增加适应症上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2457870361","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457870361?lang=zh_cn&edition=full","pubTime":"2024-08-06 00:38","pubTimestamp":1722875880,"startTime":"0","endTime":"0","summary":"康哲药业(00867.HK) 公布,甲氨蝶呤注射液增加适应症的上市许可申请已获得国家药品监督管理局批准。该产品是多种规格的预充式小容量甲氨蝶呤注射剂,获批用于治疗成人活动性类风湿关节炎。集团于今年8月获得药品注册证书。2020年9月,集团从medac Gesellschaft fur klinische Spezialpraparatem.b.H获得该产品的长期有效的独家许可权利。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-05 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230303150407041_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230303150407041_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1369037/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["SG9999015978.USD","SG9999015945.SGD","BK1593","SG9999015986.USD","SG9999004220.SGD","SG9999015952.SGD","LU2488822045.USD","BK1191","00867"],"gpt_icon":0},{"id":"2457533724","title":"迪卡斯:康哲药业获得Hepzato套件的CMS Ntap状态。","url":"https://stock-news.laohu8.com/highlight/detail?id=2457533724","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457533724?lang=zh_cn&edition=full","pubTime":"2024-08-05 20:34","pubTimestamp":1722861281,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015945.SGD","BK1191","BK4082","LU2488822045.USD","SG9999015978.USD","BK4585","BK1593","BK4588","LU2637428348.USD","DCTH","SG9999015952.SGD","SG9999015986.USD","CMS","BK4208","00867","SG9999004220.SGD"],"gpt_icon":0},{"id":"2457726498","title":"【康龙化成(03759.HK)和合作方共同对新加坡合资公司追加投资2000万美元】智通财经APP讯,康龙化成(03759.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457726498","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457726498?lang=zh_cn&edition=full","pubTime":"2024-08-05 19:53","pubTimestamp":1722858802,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0898667661.SGD","300759","LU0877626530.USD","SG9999004220.SGD","BK4208","CMS","LU0205439572.USD","SG9999015945.SGD","SG9999016042.SGD","LU2637428348.USD","BK1576","BK1593","LU1119993845.HKD","BK6523","BK4585","SG9999004360.SGD","BK6516","FSTAS.SI","SG9999015978.USD","SG9999015986.USD","LU2488822045.USD","BK6033","BK4588","SG9999000343.SGD","SG9999001135.SGD","03759","STI.SI","LU0831103253.SGD","SG9999015952.SGD","ES3.SI","BK1141","FSTM.SI","BK1191","S68.SI","00867","BK0216"],"gpt_icon":0},{"id":"2457725550","title":"康哲药业(00867):甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2457725550","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457725550?lang=zh_cn&edition=full","pubTime":"2024-08-05 19:30","pubTimestamp":1722857430,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康哲药业 发布公告,甲氨蝶呤注射液(产品)增加适应症的上市许可申请已于2024年7月30日获得国家药品监督管理局批准。甲氨蝶呤是国际公认治疗类风湿关节炎的一线首选药物和锚定药物。产品是中国首个以皮下给药方式治疗类风湿关节炎的预充式甲氨蝶呤注射液,为成人活动性类风湿关节炎患者提供更加安全、有效、便捷、精准的给药方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","SG9999015952.SGD","SG9999015978.USD","SG9999015945.SGD","BK1191","00867","BK1593","SG9999004220.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2457256277","title":"【康哲药业(00867.HK):甲氨蝶呤注射液增加类风湿关节炎适应症中国上市许可申请获批】智通财经APP讯,康哲药业(00867.","url":"https://stock-news.laohu8.com/highlight/detail?id=2457256277","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457256277?lang=zh_cn&edition=full","pubTime":"2024-08-05 19:30","pubTimestamp":1722857430,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999015945.SGD","SG9999015952.SGD","BK1593","RA","BK1191","LU2488822045.USD","SG9999015978.USD","SG9999015986.USD","00867","SG9999004220.SGD"],"gpt_icon":0},{"id":"2457742027","title":"康哲药业(00867.HK)将于8月15日召开董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2457742027","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457742027?lang=zh_cn&edition=full","pubTime":"2024-08-05 18:14","pubTimestamp":1722852860,"startTime":"0","endTime":"0","summary":"格隆汇8月5日丨康哲药业(00867.HK)公告,公司将于2024年8月15日召开公司董事会会议,其中包括考虑及拟批准公司及其附属公司截至2024年6月30日止六个月的中期业绩,及考虑派发中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408051814509f10059d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408051814509f10059d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","LU2488822045.USD","SG9999015978.USD","SG9999015952.SGD","BK1593","SG9999015986.USD","BK1191","SG9999004220.SGD","SG9999015945.SGD"],"gpt_icon":0},{"id":"2457762857","title":"南向资金8月2日净买入康哲药业10.10万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2457762857","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457762857?lang=zh_cn&edition=full","pubTime":"2024-08-05 09:31","pubTimestamp":1722821491,"startTime":"0","endTime":"0","summary":"8月2日, 南向资金增持康哲药业10.10万股,连续7日增持。截止当日收盘,港股通共持有康哲药业20938.42万股,占流通股8.57%。康哲药业近5个交易日上涨3.28%,港股通累计增持245.20万股;近20个交易日下跌1.19%,港股通累计增持1150.10万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408050939079f0ea591&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408050939079f0ea591&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015952.SGD","00867","BK1191","SG9999004220.SGD","SG9999015986.USD","BK1593","SG9999015945.SGD","SG9999015978.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cms.net.cn","stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0262},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.4414},{"period":"1year","weight":-0.3767},{"period":"ytd","weight":-0.5141}],"compareEarnings":[{"period":"1week","weight":0.0129},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.125},{"period":"6month","weight":0.0471},{"period":"1year","weight":-0.0666},{"period":"ytd","weight":0.0036}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康哲药业控股有限公司是一家主要从事医药产品的制造、推广、营销及销售业务的香港投资控股公司。其直接网络主要产品包括黛力新、优思弗、新活素、莎尔福、亿活及施图伦滴眼液等。其代理商推广网络产品包括沙多力卡、伊诺舒及喜达康等。其产品用于治疗胃病、心脏病、外伤感染、肝病及眼疾等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.011271},{"month":2,"riseRate":0.538462,"avgChangeRate":0.023783},{"month":3,"riseRate":0.5,"avgChangeRate":0.004148},{"month":4,"riseRate":0.5,"avgChangeRate":0.022243},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.00853},{"month":6,"riseRate":0.642857,"avgChangeRate":-0.002222},{"month":7,"riseRate":0.5,"avgChangeRate":-0.017281},{"month":8,"riseRate":0.428571,"avgChangeRate":0.016875},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.018636},{"month":10,"riseRate":0.571429,"avgChangeRate":0.021743},{"month":11,"riseRate":0.571429,"avgChangeRate":0.062348},{"month":12,"riseRate":0.642857,"avgChangeRate":0.043989}],"exchange":"SEHK","name":"康哲药业","nameEN":"CMS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康哲药业,00867,康哲药业股票,康哲药业股票老虎,康哲药业股票老虎国际,康哲药业行情,康哲药业股票行情,康哲药业股价,康哲药业股市,康哲药业股票价格,康哲药业股票交易,康哲药业股票购买,康哲药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康哲药业(00867)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康哲药业(00867)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}